Sep 28, 2023 / 01:45PM GMT
Charles Duncan - Cantor Fitzgerald & Co. - Analyst
Good morning, everyone. So it's the third day of the 2023 Cantor Global Healthcare Conference. And I'm really excited to be here, not only because it's been a couple of long days, but because there are some very interesting companies that we're going to be talking about today. And the first is Longboard Pharmaceuticals. So I have Kevin Lind, the company's President and CEO from Longboard. Kevin? Good to see you.
Kevin Lind - Longboard Pharmaceuticals, Inc. - President, CEO, and Director
Good to see you.
Charles Duncan - Cantor Fitzgerald & Co. - Analyst
It's a company we cover and a very exciting company for its history, but also where it's going and how it can transform with a best-in-class drug for epilepsy. So Kevin's going to run through a few slides, we'll stop him, I'll interrupt him, ask him a few questions. If the audience has any questions, please yell out at me, and then we'll carry on. Kevin?
Kevin Lind - Longboard
Longboard Pharmaceuticals Inc at Cantor Fitzgerald Global Healthcare Conference Transcript
Sep 28, 2023
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers